PET status at v0 | PET status at v2 | Clinical status at v2 | |||||||
---|---|---|---|---|---|---|---|---|---|
Aβ− | Aβ+ | p | Aβ− | Aβ+ | p | SCD | MCI | p | |
n | 114 | 15 | N/A | 107 | 22 | N/A | 114 | 15 | N/A |
Age | 64.22 ± 7.41 | 68.49 ± 4.76 | 0.03* | 65.70 ± 7.29 | 70.82 ± 5.48 | 0.002* | 65.76 ± 6.77 | 72.73. ± 8.12 | < 0.001* |
Females (%) | 71 (62.3%) | 10 (66.7%) | 0.74 | 68 (63.55%) | 13 (59.1%) | 0.69 | 72 (63.16%) | 9 (60%) | 0.85 |
Years of education | 12.58 ± 3.94 | 11.80 ± 3.99 | 0.48 | 12.56 ± 3.91 | 12.14 ± 4.16 | 0.65 | 12.80 ± 3.86 | 10.07 ± 3.83 | 0.01* |
MMSE | 29.32 ± 0.90 | 29.53 ± 0.74 | 0.39 | 29.22 ± 1.03 | 29.11 ± 1.32 | 0.72 | 29.33 ± 0.88 | 28.25 ± 1.82 | 0.06 |
APOE ε4+ (%) | 21 (18.4%) | 11 (73.7%) | < 0.001* | 21 (19.6%) | 11 (50%) | 0.003* | 24 (21.05%) | 8 (53.3%) | 0.007* |